Free Trial
NASDAQ:SNSE

Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis

Sensei Biotherapeutics logo
$9.14 -0.13 (-1.36%)
As of 07/3/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Sensei Biotherapeutics Stock (NASDAQ:SNSE)

Key Stats

Today's Range
$9.00
$9.07
50-Day Range
$5.90
$9.27
52-Week Range
$5.00
$17.40
Volume
5,809 shs
Average Volume
45,504 shs
Market Capitalization
$11.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.00
Consensus Rating
Buy

Company Overview

Sensei Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

SNSE MarketRank™: 

Sensei Biotherapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 496th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sensei Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Sensei Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($1.17) to ($0.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sensei Biotherapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sensei Biotherapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sensei Biotherapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sensei Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.54% of the float of Sensei Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sensei Biotherapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sensei Biotherapeutics has recently decreased by 93.54%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sensei Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Sensei Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.54% of the float of Sensei Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Sensei Biotherapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sensei Biotherapeutics has recently decreased by 93.54%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      23.20% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 10.50% of the stock of Sensei Biotherapeutics is held by institutions.

    • Read more about Sensei Biotherapeutics' insider trading history.
    Receive SNSE Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

    SNSE Stock News Headlines

    Elon’s BIGGEST warning yet?
    Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
    Sensei Rockets on FY ’24 Results
    Sensei Rockets on FY ’24 Results
    See More Headlines

    SNSE Stock Analysis - Frequently Asked Questions

    Sensei Biotherapeutics' stock was trading at $9.8020 at the start of the year. Since then, SNSE stock has decreased by 7.4% and is now trading at $9.0750.

    Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($5.40) earnings per share for the quarter, missing analysts' consensus estimates of ($4.20) by $1.20.

    Shares of Sensei Biotherapeutics reverse split on the morning of Tuesday, June 17th 2025.The 1-20 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. acted as the underwriters for the IPO.

    Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG), PayPal (PYPL) and Walt Disney (DIS).

    Company Calendar

    Last Earnings
    5/06/2025
    Today
    7/04/2025
    Next Earnings (Estimated)
    8/05/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:SNSE
    Fax
    N/A
    Employees
    40
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $90.00
    High Stock Price Target
    $100.00
    Low Stock Price Target
    $80.00
    Potential Upside/Downside
    +891.7%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.33
    Research Coverage
    3 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$30.16 million
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $30.52 per share
    Price / Book
    0.30

    Miscellaneous

    Free Float
    968,000
    Market Cap
    $11.43 million
    Optionable
    Not Optionable
    Beta
    0.27
    The 10 Best AI Stocks to Own in 2025 Cover

    Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

    Get This Free Report

    This page (NASDAQ:SNSE) was last updated on 7/4/2025 by MarketBeat.com Staff
    From Our Partners